<DOC>
	<DOCNO>NCT02002884</DOCNO>
	<brief_summary>The purpose study determine whether injection Botulinum toxin type A muscle one arm alone combination injection one legs effective safe treat children/adolescents ( age 2-17 year ) increase muscle tension/uncontrollable muscle stiffness ( spasticity ) due cerebral palsy .</brief_summary>
	<brief_title>Dose-response Study Efficacy Safety Botulinum Toxin Type A Treat Spasticity Arm ( ) Arm ( ) Leg ( ) Cerebral Palsy</brief_title>
	<detailed_description />
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Female male subject 2 17 year age ( inclusive ) . Uni bilateral Cerebral Palsy ( CP ) clinical need injection NT 201 treatment upper limb ( UL ) spasticity least unilaterally . Ashworth Scale ( AS ) score main clinical target pattern study : 1 . Flexed elbow : AS≥2 elbow flexor ( least unilaterally ) . and/or 2 . Flexed Wrist : AS≥2 wrist flexor ( least unilaterally ) . Clinical need accord judgment investigator one five treatment combination ( AE , show ) . AS score must ≥2 target pattern choose injection Baseline Injection Visit V2 . A. UL ( ) treatment ( GMFCS IV ) : A1 ) Unilateral treatment UL spasticity 8 U/kg BW NT 201 ( maximum 200 U ) : 1 . At least one main clinical target pattern flexed elbow ( 4 U/kg BW ) and/or flexed wrist ( 2 U/kg BW ) . 2 . Additional clinical pattern limb ( i.e. , clench fist , thumb palm , and/or pronate forearm ) remain unit maximum dose 8 U/kg BW ( maximum 200 U ) treatment single UL reach . A2 ) Bilateral treatment UL spasticity equal dose 8 U/kg BW NT 201 ( maximum 200 U ) UL . Dose per UL must distribute : 1 . At least one main clinical target pattern flexed elbow ( 4 U/kg BW ) and/or flexed wrist ( 2 U/kg BW ) . 2 . Additional clinical pattern limb ( i.e. , clench fist , thumb palm , and/or pronate forearm ) remain unit maximum dose 8 U/kg BW ( maximum 200 U ) treatment single UL reach . B . Unilateral UL unilateral low limb ( LL ) treatment ( GMFCS IV ) : B1 ) Unilateral treatment UL spasticity 8 U/kg BW NT 201 ( maximum 200 U ) : 1 . At least one main clinical target pattern flexed elbow ( 4 U/kg BW ) and/or flexed wrist ( 2 U/kg BW ) . 2 . Additional clinical pattern limb ( i.e. , clench fist , thumb palm , and/or pronate forearm ) remain unit maximum dose 8 U/kg BW ( maximum 200 U ) treatment single UL reach . plus B2 ) Ipsilateral unilateral treatment LL spasticity 8 U/kg BW NT 201 ( maximum 200 U ) . Dose LL must distribute least one clinical target pattern pes equinus , flexed knee , adduct thigh , extend great toe clinically need . C. Unilateral UL bilateral LL treatment ( GMFCS IIII ) C1 ) Unilateral treatment UL spasticity 8 U/kg BW NT 201 ( maximum 200 U ) : 1 . At least one main clinical target pattern flexed elbow ( 4 U/kg BW ) and/or flexed wrist ( 2 U/kg BW ) . 2 . Additional clinical pattern limb ( i.e. , clench fist , thumb palm , and/or pronate forearm ) remain unit maximum dose 8 U/kg BW ( maximum 200 U ) treatment single UL reach . plus C2 ) Bilateral treatment LL spasticity 12 U/kg BW ( maximum 300 U ) . Dose must distribute least one clinical target pattern pes equinus , flexed knee , adduct thigh , extend great toe , side . Dose distribution may vary side clinically need . D. Unilateral UL bilateral LL treatment ( GMFCS IV V ) D1 ) Unilateral treatment UL spasticity 8 U/kg BW NT 201 ( maximum 200 U ) : 1 . At least one main clinical target pattern flexed elbow ( 4 U/kg BW ) and/or flexed wrist ( 2 U/kg BW ) . 2 . Additional clinical pattern limb ( i.e. , clench fist , thumb palm , and/or pronate forearm ) remain unit maximum dose 8 U/kg BW ( maximum 200 U ) treatment single UL reach . plus D2 ) Bilateral treatment LL spasticity 8 U/kg BW ( maximum 200 U ) . Dose must distribute least one clinical target pattern pes equinus , flexed knee , adduct thigh , extend great toe , side . Dose distribution may vary side clinically need . E. Bilateral UL treatment bilateral LL treatment ( GMFCS IIII ) E1 ) Bilateral treatment UL spasticity equal dose 8 U/kg BW NT 201 ( maximum 200 U ) UL . Dose per UL must distribute 1. least one main clinical target pattern flexed elbow ( 4 U/kg BW ) and/or flexed wrist ( 2 U/kg BW ) 2. additional clinical pattern limb ( i.e. , clench fist , thumb palm , and/or pronate forearm ) remain unit maximum dose 8 U/kg BW ( maximum 200 U ) treatment single UL reach . plus E2 ) Bilateral treatment LL spasticity 4 U/kg BW ( maximum 100 U ) . Dose must distribute least one clinical target pattern pes equinus , flexed knee , adduct thigh , extend great toe , side . Dose distribution may vary side clinically need . Pretreated ( nonnaïve ) subject must receive BoNT treatment within last 14 week prior Screening Visit ( V1 ) indication .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Upper limb spasticity</keyword>
	<keyword>low limb spasticity</keyword>
	<keyword>combine upper low limb spasticity</keyword>
</DOC>